Newsfeed : Study Examines Failure of Merck Vaccine Trial

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Newsfeed » November 2008

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

November 4, 2008

Study Examines Failure of Merck Vaccine Trial

Testing of an experimental HIV vaccine developed by U.S. pharmaceutical company Merck was halted in September 2007 because results showed the drug may increase the risk of contracting HIV rather than prevent it. In a recent study, researchers at France’s Montpellier Institute of Molecular Genetics examined just why that vaccine trial failed; the results were published November 3 in the Journal of Experimental Medicine, Agence France-Presse reports.

According to the article, second stage of trials of the HIV-1 vaccine relied on Adenovirus 5 (Ad5)—a modified form of the common cold—to carry elements of HIV into the body, which would trigger the immune system to fight the virus and develop a natural response.

But three years after the first trial, researchers found that the HIV infection spread three times faster in those who had developed long-lasting antibodies to the common cold, which altered the response to the vaccine. In these cases, the virus came into contact with, and was able to infect, more CD4 cells because the vaccine prompted more CD4 cells to grow.

Researchers say that the faulty vaccine reached the second phase of trials because first-phase testing of the vaccine used primates, which do not naturally come into contact with the human common cold.
 

Search: Merck, vaccine, common cold, Ad5


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dave41
    Bethany
    Oklahoma


    mtaj0818
    Washington
    DC


    Fred9774
    Brooklyn
    New York


    jacob2608
    Panama City Beach
    Florida
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.